Ruprecht-Karls-Universitat Heidelberg

Ruprecht-Karls-Universitaet Heidelberg

Mtm Laboratories, Ag

Ruprecht-Karls-Universität

Matthias Kloor

Magnus Von Knebel-Doeberitz

Miriam Reuschenbach

Magnus Von Knebel Doeberitz

Peter Findeisen

Sabine Merx

Magnus Knebel-Doeberitz

Described is a vaccine for prevention and treatment of cancer characterized by microsatellite instability (MSI). The vaccine contains an MSI-specific frameshift peptide (FSP) generating humoral and cellular responses against tumor cells or a nucleic acid encoding said FSP. The vaccine of the present invention is particularly useful for the prevention/treatment of colorectal cancer, endometrial cancer, gastric cancer or small bowel cancer.

MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer

Described are particular fragments of the cyclin-dependent kinase inhibitor p16 capable of increasing IFN-&#x3b3; secretion of T cells or inducing proliferation of T cells and the use of said fragments for immunizing an individual against HPV-associated or other p16expressing carcinomas, preferably advanced carcinomas.

[object Object]

The present invention provides a method for assessment of the Microsatellite Instability (MSI) status of medically relevant conditions associated with MSI phenotype such as e.g. neoplastic lesions. The method is based on the analysis of a monomorphic T25 (CAT25) mononucleotide repeat located in the 3'-UTR of the Caspase 2 (CASP2) gene. Based on the determination of the length of the named mononucleotide repeat the presence or absence of MSI may be assessed. Determination of the length is performed in a single PCR procedure. Alternatively an enhanced assessment could be performed by combining the CAT25 marker with further markers such as BAT25 and BAT26 in a single multiplex PCR process.

Compounds and methods for assessment of microsatellite instability (MSI) status

Growing community of inventors

Ludwigshafen, Germany

Matthias Kloor